Treatment name: SPK-8011 Administration: Being tested in hemophilia A as a one-time intravenous infusion Clinical testing: Previously tested in a Phase 1/2 clinical trial; Phase 3 clinical trial underwayHow does SPK-8011 work in hemophilia?
研究结果显示,dirloctocogene samoparvovec给药后7年的耐受性良好,FVIII持久表达,以及具有临床意义的ABR和AIR减少。 参考来源:Stacy E. Croteau, et al. Long-Term Follow-Up of Participants in the Phase I/II Trial of Dirlocto...
Rapid Clearance of Vector Following AAV-Mediated FVIII Gene Transfer in the Phase I/II Trial of SPK-8011 in People with Hemophilia Adoi:10.1182/blood-2022-159027Huyen TranM. EysterS. CroteauM. RagniB. Samelson-JonesS. SullivanJ. Rasko...
Learn more about Spark® Therapeutics’ progress and explore our recent announcements and resources.For additional media inquiries, please contact: communications@sparktx.com or call 1-855-SPARKTX / +1 215-220-9300.Coming Soon: Spark®’s Gene ...